Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Gene-edited babies: Chinese Academy of Medical Sciences’ response and action

CRISPR-Cas9, a powerful tool for genome editing, has provided novel strategies and potential for treating human diseases. However, the ethical challenges remain unsolved for many clinical applications. As researchers from the Chinese Academy of Medical Sciences, the national biomedical research institution in China, we and our colleagues are deeply concerned about media reports of the claim of the first gene-edited twin babies “immune to HIV” by Jiankui He and colleagues.1 At the Second International Summit on Human Genome Editing in Hong Kong, China, Jiankui He disclosed their work on CRISPR-Cas9 mediated genome editing of the CCR5 gene in human germ cells and embryos.